RESNA position on the application of power mobility devices for pediatric users.

  • PubMed
  • May 4, 2025
  • 0 Comments

RESNA position on the application of power mobility devices for pediatric users.

Autor: Rosen, Lauren; Plummer, Teresa; Sabet, Andrina; Lange, Michelle L.; Livingstone, Roslyn

Publication year: 2023

Assistive technology : the official journal of RESNA

issn:1949-3614 1040-0435

doi: 10.1080/10400435.2017.1415575


Abstract:

This paper serves as an update to the previous RESNA Position on the Application of Power Wheelchairs for Pediatric Users with more current and additional scientific literature. This document contains typical clinical applications and best evidence from the literature supporting the application of power mobility (PM) for young children and to assist practitioners in decision-making and justification. It is RESNA’ s position that age, limited vision or cognition, behavioral issues, and the ability to walk or propel a manual wheelchair short distances should not, in and of themselves, be used as discriminatory factors against providing PM for children. RESNA recommends early utilization of PM for children with mobility limitations as medically necessary, to promote integration and psycho-social development, reduce passive dependency, and to enhance participation, function, and independence.

Language: eng

Rights:

Pmid: 29232181

Tags: Humans; Child; Child, Preschool; Cognition; *Wheelchairs; mobility; Mobility Limitation; pediatric mobility; pediatric wheelchair; power wheelchair; Walking

Link: https://pubmed.ncbi.nlm.nih.gov/29232181/

Related Posts

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial

Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial

Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

West Johnston High and Triangle Math and Science Academy Compete in Brain Game Playoff

  • May 10, 2025
West Johnston High and Triangle Math and Science Academy Compete in Brain Game Playoff

New Study Reveals ‘Ice Piracy’ Phenomenon Accelerating Glacier Loss in West Antarctica

  • May 10, 2025
New Study Reveals ‘Ice Piracy’ Phenomenon Accelerating Glacier Loss in West Antarctica

New Study Suggests Certain Chemicals Disrupt Circadian Rhythm Like Caffeine

  • May 10, 2025
New Study Suggests Certain Chemicals Disrupt Circadian Rhythm Like Caffeine

Hospitalization Rates for Infants Under 8 Months Drop Significantly, Data Shows

  • May 10, 2025
Hospitalization Rates for Infants Under 8 Months Drop Significantly, Data Shows

Fleet Science Center Alters Anniversary Celebrations After Losing Grant Funding

  • May 10, 2025
Fleet Science Center Alters Anniversary Celebrations After Losing Grant Funding

How Microwaves Actually Work: A Scientific Breakdown

  • May 10, 2025
How Microwaves Actually Work: A Scientific Breakdown